Information Provided By: 
Fly News Breaks for October 8, 2015
NBIX
Oct 8, 2015 | 10:15 EDT
JPMorgan analyst Anupam Rama views this morning's positive data from the phase 3 KINECT 3 study of NBI-98854 in tardive dyskinesia as "game-changing" for Neurocrine Biosciences. NBI-98854 is the key valuation driver for the company, Rama tells investors in a research note. He thinks shares could see a "steady rally" on the data and upped his price target for the stock to $70 from $66. The analyst reiterates an Overweight rating on Neurocrine.
News For NBIX From the Last 2 Days
